

AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:	APCBSSE/0053	
Drug name and formulations:	Paliperidone palmitate 3-monthly injection (Trevicta®)	
Criteria	Example	Committee Consensus
Patient Safety	<i>Potential for abuse, toxicity, significant drug interactions</i>	In line with other long-acting antipsychotic injections, notably the paliperidone monthly injection. The 12x monthly injection period provides some additional reassurance that the patient can tolerate the agent before moving onto the 3-monthly injection.
Clinical effectiveness	<i>Established licensed product</i>	Same evidence base as other similar agents on the formulary; better than placebo but no comparative trials.
Strength of evidence		Evidence sufficient to get product licence.
Cost effectiveness or resource impact	£	More expensive than first generation long-acting antipsychotic injections, but cost neutral compared to monthly paliperidone injection. Evidence provided during application of scrutiny to ensure cost-effective use.
Place of therapy relative to available treatments	<i>1/2nd tier</i>	3rd line therapy, well defined during presentation.
National guidance and priorities	<i>NICE, MTRAC</i>	Accepted by SMC for use within NHS Scotland in September 2016.
Local health priorities	<i>CCG views</i>	CCGs supportive.
Equity of access	<i>Equality assessment</i>	Offers a wider choice for patients with psychiatric illness.
Stakeholder views	<i>Define wider groups to be engaged</i>	Psychiatrists at Forward Thinking Birmingham (FTB) are supportive.
Implementation requirements	<i>Requires, RICAD ESCA etc.</i>	N/A

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	

Formulary status (RAG) and rationale	Approved as Red, in line with other long-acting antipsychotic depot injections already on formulary.
Implementation requirements:	
Implementation monitoring:	